Structure Therapeutics disclosed Phase 2 results for aleniglipron, an oral once‑daily GLP‑1 receptor agonist, reporting up to roughly 16% placebo‑adjusted weight loss at 44 weeks. The company plans to advance the asset into Phase 3 later this year and positions the oral candidate as a direct competitor to injectable GLP‑1 and GLP‑1/GIP agents. Trial details show reproducible weight‑loss signals consistent with a best‑in‑class case for an oral format; Structure will now design registrational programs and prepare for larger safety and durability assessments. The data further shift competitive dynamics as pharmaceutical companies race to deliver non‑injectable obesity therapies with comparable efficacy to injectables. Payers and regulators will focus on long‑term safety, cardiovascular outcomes and real‑world adherence in evaluating the clinical and commercial potential of an oral GLP‑1 pill.